These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

664 related items for PubMed ID: 17473568

  • 1. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study.
    Pamuk GE, Turgut B, Pamuk ON, Vural O, Demir M, Cakir N.
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):297-302. PubMed ID: 17473568
    [Abstract] [Full Text] [Related]

  • 2. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A, Abou-Raya S, Helmii M.
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [Abstract] [Full Text] [Related]

  • 3. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP.
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [Abstract] [Full Text] [Related]

  • 4. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
    Fontenelle SM, Kayser C, Pucinelli ML, Andrade LE.
    Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
    [Abstract] [Full Text] [Related]

  • 5. Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: effect of cold exposure.
    Cracowski JL, Carpentier PH, Imbert B, Cachot S, Stanke-Labesque F, Bessard J, Bessard G.
    Arthritis Rheum; 2002 May; 46(5):1319-23. PubMed ID: 12115239
    [Abstract] [Full Text] [Related]

  • 6. Laser Doppler-recorded venoarteriolar reflex in Raynaud's phenomenon.
    Stoyneva Z.
    Auton Neurosci; 2004 Nov 30; 116(1-2):62-8. PubMed ID: 15556839
    [Abstract] [Full Text] [Related]

  • 7. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M, Pozzi MR, Bernareggi M, Montani N, Allevi E, Catena L, Cugno M, Bottasso B, Stabilini R.
    J Rheumatol; 2001 Apr 30; 28(4):786-94. PubMed ID: 11327251
    [Abstract] [Full Text] [Related]

  • 8. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jiménez SA, White B, Seibold JR, Wigley FM, Scleroderma Clinical Trials Consortium.
    Arthritis Rheum; 2002 Sep 30; 46(9):2410-20. PubMed ID: 12355489
    [Abstract] [Full Text] [Related]

  • 9. [Platelet function study in primary Raynaud's phenomenon and Raynaud's phenomenon associated with scleroderma].
    Cuenca R, Fernández-Cortijo J, Lima J, Fonollosa V, Simeón CP, Pico M, Soriano B, Vilardell M.
    Med Clin (Barc); 1990 Dec 08; 95(20):761-3. PubMed ID: 2151867
    [Abstract] [Full Text] [Related]

  • 10. Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon.
    Marasini B, Casari S, Bestetti A, Maioli C, Cugno M, Zeni S, Turri O, Guagnellini E, Biondi ML.
    J Rheumatol; 2000 Nov 08; 27(11):2621-3. PubMed ID: 11093443
    [Abstract] [Full Text] [Related]

  • 11. Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis.
    Mok MY, Cheung BM, Lo Y, Leung RY, Wong WS, Lau CS.
    J Rheumatol; 2007 Nov 08; 34(11):2224-9. PubMed ID: 17937467
    [Abstract] [Full Text] [Related]

  • 12. Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders.
    Maricq HR, Weinrich MC, Valter I, Palesch YY, Maricq JG.
    J Rheumatol; 1996 Dec 08; 23(12):2068-78. PubMed ID: 8970043
    [Abstract] [Full Text] [Related]

  • 13. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis.
    Sulli A, Soldano S, Pizzorni C, Montagna P, Secchi ME, Villaggio B, Seriolo B, Brizzolara R, Cutolo M.
    J Rheumatol; 2009 Jun 08; 36(6):1235-9. PubMed ID: 19369451
    [Abstract] [Full Text] [Related]

  • 14. Spontaneous chromosome damage (micronuclei) in systemic sclerosis and Raynaud's phenomenon.
    Porciello G, Scarpato R, Ferri C, Storino F, Cagetti F, Morozzi G, Bellisai F, Migliore L, Marcolongo R, Galeazzi M.
    J Rheumatol; 2003 Jun 08; 30(6):1244-7. PubMed ID: 12784397
    [Abstract] [Full Text] [Related]

  • 15. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis.
    Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI.
    J Rheumatol; 1994 Aug 08; 21(8):1477-83. PubMed ID: 7983650
    [Abstract] [Full Text] [Related]

  • 16. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E, Letizia C, Proietti M, Aversa A, Menghi G, Rossi C, Torella E, Cotesta D, Petramala L, Bruzziches R, Spera G, Pisarri S, Salsano F.
    J Biol Regul Homeost Agents; 2009 Aug 08; 23(1):23-9. PubMed ID: 19321043
    [Abstract] [Full Text] [Related]

  • 17. Increased circulating platelet-neutrophil, platelet-monocyte complexes, and platelet activation in patients with ulcerative colitis: a comparative study.
    Pamuk GE, Vural O, Turgut B, Demir M, Umit H, Tezel A.
    Am J Hematol; 2006 Oct 08; 81(10):753-9. PubMed ID: 16941615
    [Abstract] [Full Text] [Related]

  • 18. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A, Burmester GR, Huscher D, Sunderkötter C, Riemekasten G.
    J Rheumatol; 2008 Sep 08; 35(9):1830-7. PubMed ID: 18634152
    [Abstract] [Full Text] [Related]

  • 19. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE, Shea B, Welch V, Fenlon D, Pope JE.
    Arthritis Rheum; 2001 Aug 08; 44(8):1841-7. PubMed ID: 11508437
    [Abstract] [Full Text] [Related]

  • 20. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon.
    Kallenberg CG, Vellenga E, Wouda AA, The TH.
    J Rheumatol; 1982 Aug 08; 9(6):878-84. PubMed ID: 7161779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.